Johnson & Johnson Q4 Earnings Beat, But Stock Falls on Stelara

Johnson & Johnson reports Q4 earnings of $2.46/share, beating estimates with 9.1% sales growth to $24.6B, but stock falls 3% on Stelara patent loss concerns.